Aura Biosciences Expanded Access Policy
Aura Biosciences is committed to developing safe and effective therapies to transform the lives of patients with ocular cancers. Our goal is to successfully advance and seek marketing approval for innovative ocular cancer treatments and to provide patients with broad access to our future products. We are currently conducting clinical trials to assess the safety and effectiveness of our first investigational drug candidate in human subjects.
Expanded Access, also known as Compassionate Use, refers to a pathway in which patients with serious or immediately life-threatening diseases or conditions may gain access to an investigational product outside the context of participation in clinical trials.
At this time, Aura Biosciences believes that participation in one of our clinical trials is the most appropriate way to access our investigational therapy for ocular cancer, and therefore none of our investigational products are currently available under expanded access programs. You and your health care provider may learn more about our clinical trials by going to the pipeline section of our website, or visiting www.clinicaltrials.gov and searching for Aura Biosciences.
If you are a health care provider who is interested in learning more about one of our investigational therapies, or a physician with questions about participation in one of our clinical trials, please submit a request to MedicalAffairs@aurabiosciences.com. The company will acknowledge questions as soon as possible, usually within 5 business days of receipt.
Aura Biosciences may revise this policy at any time. We continue to push forward in our development programs with a goal to deliver innovative products to the largest number of patients in the shortest amount of time.